Antibiotic Treatment for Bacterial Dysentery in Children

First-line Treatment

• The World Health Organization recommends ciprofloxacin as the first-line antibiotic treatment for bacterial dysentery in children, with a dosage of 15 mg/kg per dose, oral administration 1
• Ciprofloxacin is considered highly effective and appropriate for shigellosis in children, despite concerns about potential adverse effects like arthropathy, according to the WHO Working Group 1

Second-line Options

• Azithromycin is a second-line option, with a dosage of 10 mg/kg on day 1, followed by 5 mg/kg daily for 4 days, or a single dose of 1000 mg, and has been shown to be effective against shigellosis in pediatric patients 1, 2
• Cefixime is an appropriate oral alternative when ciprofloxacin resistance is high, and is effective against shigellosis in pediatric patients 1

Treatment Considerations

• Antibiotic selection should be guided by local resistance patterns, particularly in regions like Southeast Asia where ciprofloxacin resistance is high, according to the WHO and Journal of Travel Medicine 1, 2
• Current WHO recommendations for shigellosis treatment have been shown to reduce clinical failure rates by 82% 1
• Antimotility agents, such as loperamide, should be avoided in children with acute dysentery 3

Resistance Patterns to Consider

• Higher resistance rates to antibiotics are observed in Asia-Africa compared to Europe-America, with ciprofloxacin resistance rates reaching 5.0% in Asia-Africa 1
• Ceftriaxone resistance rates were 2.5% in Asia-Africa versus 0.4% in Europe-America, with rates reaching 14.2% in Asia-Africa after 2007 1

Special Populations

• For children with severe illness or those who are immunocompromised, parenteral therapy with ceftriaxone may be preferred initially, according to the Journal of Travel Medicine 2

Duration of Treatment

• 3-5 days of treatment is typically sufficient for uncomplicated cases, and single-dose regimens may be considered for mild to moderate cases to improve compliance, according to the Journal of Travel Medicine 2

Monitoring and Follow-up

• Monitor for potential adverse effects, particularly with fluoroquinolones, such as ciprofloxacin 1